Fatigue in neurological disorders
暂无分享,去创建一个
[1] M. Trimble. Behavioral Neurology, 4th ed. , 2004 .
[2] A. Zenzola,et al. Fatigue in Parkinson’s disease , 2003, Neurological Sciences.
[3] N. Secher,et al. Cerebral Metabolism is Influenced by Muscle Ischaemia During Exercise in Humans , 2003, Experimental physiology.
[4] E. Tolosa,et al. Cognitive effects of unilateral posteroventral pallidotomy: A 4‐year follow‐up study , 2003, Movement disorders : official journal of the Movement Disorder Society.
[5] E. D. de Haan,et al. Cognitive functioning in patients with a small infarct in the brainstem , 2003, Journal of the International Neuropsychological Society.
[6] B. Condon,et al. Proton magnetic resonance spectroscopy of basal ganglia in chronic fatigue syndrome , 2003, Neuroreport.
[7] M Rovaris,et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. , 2003, Brain : a journal of neurology.
[8] T. Scammell,et al. The neurobiology, diagnosis, and treatment of narcolepsy , 2003, Annals of neurology.
[9] J. Hajnal,et al. Relative increase in choline in the occipital cortex in chronic fatigue syndrome , 2002, Acta psychiatrica Scandinavica.
[10] Beth Borowsky,et al. Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist , 2002, Nature Medicine.
[11] M. Rupp,et al. Modafinil in treatment of fatigue in multiple sclerosis , 2002, Journal of Neurology.
[12] Peter Campbell,et al. The Madness of Adam and Eve: How Schizophrenia Shaped Humanity David Horrobin The Madness of Adam and Eve: How Schizophrenia Shaped Humanity Corgi Books £8.99;346pps055299930X055299930X , 2002 .
[13] N. Ling,et al. Pharmacological evidence supporting a role for central corticotropin-releasing factor(2) receptors in behavioral, but not endocrine, response to environmental stress. , 2002, The Journal of pharmacology and experimental therapeutics.
[14] R. Yehuda. Current status of cortisol findings in post-traumatic stress disorder. , 2002, The Psychiatric clinics of North America.
[15] E. Glader,et al. Poststroke Fatigue: A 2-Year Follow-Up Study of Stroke Patients in Sweden , 2002, Stroke.
[16] G. Griebel,et al. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[17] R. Felix. Insights from Mouse Models of Absence Epilepsy into Ca2+ Channel Physiology and Disease Etiology , 2002, Cellular and Molecular Neurobiology.
[18] G. Scotti,et al. Functional Magnetic Resonance Imaging Correlates of Fatigue in Multiple Sclerosis , 2002, NeuroImage.
[19] I. Appollonio,et al. Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.
[20] T. Gordon,et al. Effect of exercise on stability of chronically enlarged motor units , 2002, Muscle & nerve.
[21] H. Nagaraja,et al. Efficacy and safety of modafinil (Provigil®) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study , 2002, Journal of neurology, neurosurgery, and psychiatry.
[22] R. Haller,et al. Venous oxygen levels during aerobic forearm exercise: An index of impaired oxidative metabolism in mitochondrial myopathy , 2002, Annals of neurology.
[23] M. Andersen,et al. Exercise and multiple sclerosis: physiological, psychological, and quality of life issues. , 2001, The Journal of sports medicine and physical fitness.
[24] P. Whiting,et al. Interventions for the treatment and management of chronic fatigue syndrome: a systematic review. , 2001, JAMA.
[25] David H. Miller,et al. Fatigue is not associated with raised inflammatory markers in multiple sclerosis , 2001, Neurology.
[26] Julien Bogousslavsky,et al. Fatigue after Stroke: A Major but Neglected Issue , 2001, Cerebrovascular Diseases.
[27] C. Rice,et al. Quadriceps muscle function and fatigue in women with Addison's disease , 2001, Muscle & nerve.
[28] Robert L. Royall,et al. Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride: preliminary findings. , 2001, Archives of general psychiatry.
[29] J. Oger,et al. Potassium channel antibodies in two patients with reversible limbic encephalitis , 2001, Annals of neurology.
[30] P. Sullivan,et al. A Twin Study of Chronic Fatigue , 2001, Psychosomatic medicine.
[31] Filippo Martinelli-Boneschi,et al. Fatigue in Multiple Sclerosis Is Associated with Abnormal Cortical Activation to Voluntary Movement—EEG Evidence , 2001, NeuroImage.
[32] G. Comi,et al. Physiopathology and treatment of fatigue in multiple sclerosis , 2001, Journal of Neurology.
[33] Susan K. Johnson,et al. Longitudinal Assessment of Neuropsychological Functioning, Psychiatric Status, Functional Disability and Employment Status in Chronic Fatigue Syndrome , 2001, Applied neuropsychology.
[34] J. Pearn. Neurology of ciguatera , 2001, Journal of neurology, neurosurgery, and psychiatry.
[35] L. E. Elkins,et al. Fatigue and declines in cognitive functioning in multiple sclerosis , 2000, Neurology.
[36] A. Chaudhuri,et al. Fatigue and basal ganglia , 2000, Journal of the Neurological Sciences.
[37] R. L. Bruno,et al. Word finding difficulty as a post-polio sequelae. , 2000, American journal of physical medicine & rehabilitation.
[38] R. Blakely,et al. Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. , 2000, The New England journal of medicine.
[39] R I Grossman,et al. Total brain N-acetylaspartate , 2000, Neurology.
[40] A. Tomoda,et al. Chronic fatigue syndrome in childhood , 2000, Brain and Development.
[41] G. Alarcón,et al. Is Chiari malformation associated with increased levels of substance P and clinical symptoms in persons with fibromyalgia? , 1999, Arthritis and rheumatism.
[42] P. Schmitz,et al. Fatigue in immune-mediated polyneuropathies , 1999, Neurology.
[43] T. Munsat,et al. A multicenter, randomized, double-blinded trial of pyridostigmine in postpolio syndrome , 1999, Neurology.
[44] H. Fankhauser,et al. Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson's disease: neuropsychological and neurological side effects. Report of four cases and review of the literature. , 1999, Journal of neurosurgery.
[45] O. Sharma. Fatigue and sarcoidosis. , 1999, The European respiratory journal.
[46] J. Stewart,et al. Orthostatic Intolerance in Adolescent Chronic Fatigue Syndrome , 1999, Pediatrics.
[47] A. Algra,et al. Decreased capacity for mental effort after single supratentorial lacunar infarct may affect performance in everyday life , 1998, Journal of neurology, neurosurgery, and psychiatry.
[48] R. L. Bruno,et al. Parallels between post-polio fatigue and chronic fatigue syndrome: a common pathophysiology? , 1998, The American journal of medicine.
[49] R G Hill,et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. , 1998, Science.
[50] J. Rothwell,et al. An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis. , 1998, Brain : a journal of neurology.
[51] R. Poland,et al. Proton spectroscopy in myotonic dystrophy: correlations with CTG repeats. , 1998, Archives of neurology.
[52] B. McEwen. Protective and damaging effects of stress mediators. , 1998, The New England journal of medicine.
[53] A. McComas,et al. Early and late losses of motor units after poliomyelitis. , 1997, Brain : a journal of neurology.
[54] W. Ammann,et al. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue , 1997, Neurology.
[55] Susan K. Johnson,et al. Cognitive functioning is impaired in patients with chronic fatigue syndrome devoid of psychiatric disease. , 1997, Journal of neurology, neurosurgery, and psychiatry.
[56] J C Rothwell,et al. An electrophysiological study of the mechanism of fatigue in multiple sclerosis. , 1997, Brain : a journal of neurology.
[57] E. Kandel,et al. Essentials of Neural Science and Behavior , 1996 .
[58] R. L. Bruno,et al. Bromocriptine in the treatment of post-polio fatigue: a pilot study with implications for the pathophysiology of fatigue. , 1996, American journal of physical medicine & rehabilitation.
[59] R. Adams,et al. Principles of Neurology , 1996 .
[60] M. Latash,et al. Myogenic and Central Neurogenic Factors in Fatigue in Multiple Sclerosis , 1996, Multiple sclerosis.
[61] J. Dambrosia,et al. A Double‐Blind, Placebo‐Controlled Trial of High‐Dose Prednisone for the Treatment of Post‐Poliomyelitis Syndrome , 1995, Annals of the New York Academy of Sciences.
[62] R. Sapolsky,et al. Pathophysiology of a Central Cause, of Post‐Polio Fatigue a , 1995, Annals of the New York Academy of Sciences.
[63] J. Dambrosia,et al. A Double‐Blind, Placebo‐Controlled, Trial of Amantadine for the Treatment, of Fatigue in Patients with the, Post‐Polio Syndrome , 1995, Annals of the New York Academy of Sciences.
[64] T. Rummans,et al. Postural tachycardia syndrome (POTS). , 1995, Neurology.
[65] Ian Hickie,et al. The Chronic Fatigue Syndrome: A Comprehensive Approach to Its Definition and Study , 1994, Annals of Internal Medicine.
[66] W. Wayt Gibbs. More fun than a root canal. , 1993, Scientific American.
[67] J. DeLuca,et al. The neuropsychology of post-polio fatigue. , 1993, Archives of physical medicine and rehabilitation.
[68] R. Roos,et al. Diurnal effects of motor activity and fatigue in Parkinson's disease. , 1993, Journal of neurology, neurosurgery, and psychiatry.
[69] T. Birk,et al. Poliomyelitis and the post-polio syndrome: exercise capacities and adaptation--current research, future directions, and widespread applicability. , 1993, Medicine and science in sports and exercise.
[70] T. Dinan. Studying brain receptor function: a neuroendocrine approach , 1993, Irish Journal of Psychological Medicine.
[71] B. Weinshenker,et al. A double‐blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis , 1992, Neurology.
[72] P Sandroni,et al. 'Fatigue' in patients with multiple sclerosis. Motor pathway conduction and event-related potentials. , 1992, Archives of neurology.
[73] D. Eckland,et al. Paradoxical responses of hypothalamic corticotropin-releasing factor (CRF) messenger ribonucleic acid (mRNA) and CRF-41 peptide and adenohypophysial proopiomelanocortin mRNA during chronic inflammatory stress. , 1992, Endocrinology.
[74] M. Taussig. The Nervous System , 1991 .
[75] S. Olejnik,et al. Effect of treatment and noncompliance on post-polio sequelae. , 1991, Orthopedics.
[76] N. Larocca,et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. , 1989, Archives of neurology.
[77] B. Weinshenker,et al. A Randomized Controlled Trial of Amantadine in Fatigue Associated With Multiple Sclerosis , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[78] T. J. Murray,et al. Amantadine Therapy for Fatigue in Multiple Sclerosis , 1985, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[79] T D Noakes,et al. Hypothalamic dysfunction in overtrained athletes. , 1985, The Journal of clinical endocrinology and metabolism.
[80] G. Kraft,et al. Symptomatic fatigue in multiple sclerosis. , 1984, Archives of physical medicine and rehabilitation.
[81] Adrian M. S. Piper. A Distinction without a Difference , 1982 .
[82] Zeliha Ünlü. Myotonic dystrophy , 1981, The Ulster Medical Journal.
[83] L. Brain. The Nervous System , 1963, Nature.
[84] J. Lefaucheur,et al. [Pathophysiology and treatment of fatigue in multiple sclerosis]. , 2006, Revue neurologique.
[85] Lauren B. Krupp,et al. Fatigue in Multiple Sclerosis , 2003, CNS drugs.
[86] David F. Horrobin,et al. The Madness of Adam and Eve: How Schizophrenia Shaped Humanity , 2002 .
[87] A. Chaudhuri,et al. Neurological Dysfunction in Chronic Fatigue Syndrome , 2000 .
[88] R. Jordan,et al. Treatments for fatigue in multiple sclerosis: a rapid and systematic review. , 2000, Health technology assessment.
[89] R. L. Bruno. Paralytic vs. "nonparalytic" polio: distinction without a difference? , 2000, American journal of physical medicine & rehabilitation.
[90] F. Nollet,et al. A multicenter, randomized, double-blinded trial of pyridostigmine in postpolio syndrome. , 2000, Neurology.
[91] T. Dinan,et al. The neuroendocrinology of chronic fatigue syndrome: focus on the hypothalamic-pituitary-adrenal axis. , 1999, Functional neurology.
[92] C. U. M. Smith,et al. Elements of molecular neurobiology , 1989 .
[93] B. Giesser. Multiple sclerosis. Current concepts in management. , 1985, Drugs.
[94] D. Denny-Brown. The basal ganglia and their relation to disorders of movement , 1962 .